Peer-reviewed veterinary case report
New metaflumizone plus amitraz spot-on treats sarcoptic mange in dogs
By Fourie, L J et al.·Published in Veterinary parasitology·2007·ClinVet International·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of sarcoptic mange in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with sarcoptic mange, a skin condition caused by mites, were treated with a new spot-on medication that combines metaflumizone and amitraz. Sixteen dogs were divided into two groups; one received the treatment twice a month while the other was treated every two weeks. Both treatment schedules significantly reduced the number of mites and improved the dogs' skin condition. By the end of the study, 75% of the dogs treated monthly and 83% of those treated bi-weekly showed no signs of mites or mange.
People also search for: dog sarcoptic mange treatment · metaflumizone amitraz for dogs · how to treat dog skin mites
Abstract
A novel spot-on formulation containing metaflumizone plus amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) was evaluated for efficacy against sarcoptic mange mites in naturally infested dogs. Sixteen dogs were allocated to two equal groups and were housed individually. Eight of the dogs were treated topically with metaflumizone plus amitraz at the proposed minimum dose rate (20mg/kg of each of metaflumizone and amitraz, at a dose volume of 0.133ml/kg) on Days 0 and 28. The other eight were treated with metaflumizone plus amitraz at the proposed minimum dose rate on Days 0, 14, 28 and 42. To enumerate Sarcoptes scabiei mites, skin scrapings were taken on each of Days 2, 14, 28, 42 and 56. Clinical signs of mange and the extent of sarcoptic lesions were evaluated on each dog when scrapings were made. Evaluation of the efficacy of the treatment was based on the absence of mites supported by the absence of clinical signs associated with canine sarcoptic mange. Treatment with metaflumizone plus amitraz at the minimum proposed dose rate at monthly (two treatments) or two-weekly (four treatments) intervals resulted in a rapid reduction of mites and improved clinical signs. The overall cure rates at Day 56, based on zero mite counts and/or resolution of clinical signs were 75% and 83% of dogs for the monthly and two-weekly regimens, respectively.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17931787/